Although coronary atherosclerosis is the common process underlying virtually all the clinical manifestations of ischemic heart disease, a clear distinction between acute coronary syndromes and chronic, stable coronary disease is traditionally made. Plaque disruption with different degrees of thrombus formation is known to be responsible for most cases of instability.1 As a consequence, antithrombotic therapy with antiplatelet, anticoagulant, and fibrinolytic agents is firmly established in these situations. In patients with stable coronary artery disease, angina pectoris results from an increase in myocardial oxygen consumption with different degrees of superimposed vasoconstriction.2 Accordingly, combination therapy with 3-blockers, nitrates, and calcium blockers has gained popularity. However, coronary atherosclerosis is a chronic process of continuous remodeling of the arterial tree due to the dynamic occurrence of types I-II and III vascular injury.3 Even in the presence of mild vascular injury, the potential exists for platelets to become attached and blood coagulation to be initiated. Re- cently, it has been shown in patients with stable coronary artery disease that platelet activation takes place across the coronary bed in response to rapid atrial pacing, provided that >50% narrowing in one or more branches is present.4 In an autopsy study of patients with coronary artery disease who died of noncardiac causes, Davies et al5 found that 17% of patients had fissures in atherosclerotic plaques, and in some cases, overlying thrombi were found as well. Platelet adhesion and aggregation in turn lead to the release of a host of vasoactive substances such as thrombin, serotonin, thromboxane A2, ADP, and platelet-activating factor, which exert a vasoconstrictive effect either through the enhancement of endothelium-derived contracting factors or directly.6-9 Thus, a "continuum" exists between stable and unstable coronary disease, in terms of both vascular injury and clinical manifestations.
On the basis of these arguments, we designed a trial to investigate whether myocardial ischemia can be improved after long-term treatment with low molecular weight heparin (Parnaparin) in patients with stable coronary artery disease and reproducible effort-induced myocardial ischemia.
Methods Patients
Patients aged 40 to 79 years who had experienced anginal symptoms of a stable pattern for a minimum of 3 months and were not currently evaluated for coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty were considered for the study. All patients had angiographically proven coronary artery disease, and objective demonstration of ischemia during exercise testing was mandatory. The exclusion criteria comprise the presence of any clinically important concomitant disease (in particular, myocardial infarction within the previous 3 months; renal impairment, described as serum creatinine >2.0 mg/dL; hepatic function impairment, defined as aspartate transaminase or alanine transaminase enzyme results >15% above the upper normal limit and deemed to be clinically significant; anemia, defined as a hemoglobin concentration of <12 g/dL; hypotension, defined as standing systolic blood pressure <100 mm Hg; and hypertension, defined as systolic blood pressure >200 mm Hg or diastolic blood pressure > 110 mm Hg), contraindications to the use of anticoagulants (history of previous significant bleeding or malignancy), and/or the presence of confounding factors for the interpretation of the ECG (patients with left ventricular hypertrophy and resting ST-T wave abnormalities on the ECG, predominant cardiac rhythm other than sinus rhythm, concurrent treatment with digoxin). All 12) . Twelve-lead ECG recording and at the end of each minute during exercise, at the point of 1 mm (0.1 mV) ST segment depression, at peak exercise, and 3 and 6 minutes into the recovery period. Three ECG leads were monitored continuously before and during exercise and for 10 minutes into recovery. All tests were performed at the same time of day, 4 hours after the last dose of treatment for each patient. A positive exercise test diagnostic of myocardial ischemia was defined as horizontal or downsloping ST segment depression >1 mm measured 80 milliseconds after the J point with respect to the resting value. The exercise test was stopped in the event of chest pain of moderate severity or inability of the patient to exercise further. For each exercise test, the level of the ST segment was calculated after signal averaging by a computer-assisted system in all 12 leads every minute with an accuracy of 0.1 mm. The lead showing the greatest ST segment depression was selected for analysis. The values then measured were exercise time (minutes), amount of ST segment depression at peak exercise (mm), and the heart rate-blood pressure product (beats per minute xmm Hg) at the start of 1-mm ST segment depression and at peak exercise. The exercise tests were analyzed by investigators blinded to the treatment. The results of the two baseline examinations were averaged for the purpose of analysis.
Hemostasis Analyses and Biochemistry
Venous blood was collected by clean venipuncture through an 18-gauge needle and without tourniquet, if possible. The first 2 mL were discarded. Anti-Xa activity was assayed from blood collected in tubes containing sodium citrate 3.8%, according to the antifactor-Xa assay of Teien et a112 and Teien and Lie13 (Coatest Kabivitrum; Stockholm, Sweden). The aPTT was determined automatically on a MLA Electra 1000 C coagulometer using as reagent Actin FS (Dade; supplied by Baxter, Milan, Italy). The fibrinopeptide A concentration was determined after nine parts of whole blood were mixed in a plastic tube with one part of anticoagulant containing in each milliliter 32 mg Tris-citrate, 1000 IU heparin, and 1 TIU aprotinin. Samples were centrifuged within 10 minutes at 3000 rpm for 10 minutes; plasma was stored at -30°after being depleted of fibrinogen by bentonite absorption. Fibrinopeptide A levels were measured by an enzyme-immunoassay within 1 month (Stago; supplied by Boeringer Biochemia, Milan, Italy). Blood samples were drawn before treatment allocation (baseline) and 4 hours after the first injection of either Parnaparin or placebo and after 1 to 2 and 3 months (always 4 hours after the injection). Fibrinogen (coagulation rate assay of Clauss) and the principal biochemical data were measured at the baseline and after 3 months.
Platelet Aggregation
Blood for ex vivo platelet aggregation was collected into a 10-mL syringe and mixed with sodium citrate solution (3.8%) and diluted 1:1 with 0.9% NaCl. Samples were obtained before the first dose, 4 hours after the first dose, and after 3 months (4 hours after the last injection). All aggregations were performed in a dualchannel aggregometer (Chrono-log Corporation; supplied by Mascia-Brunelli, Milan, Italy) at 37°C with constant stirring of diluted whole blood at 1000 rpm.
blood pressure measurement (cuff) were taken at rest, Quantitative analysis of aggregation was determined as the maximum change in electrical impedance (fl) after addition of agonist. As aggregating agents, we used ADP (10 and 20 lmol), collagen (2 and 5 ,ug), and human a-thrombin (0.1 U/mL).
Bleeding and Template Bleeding Time
The template bleeding time was measured before, after the first injection, and after 1 to 2 and 3 months, always 4 Fig 1) , whereas it was unchanged in the placebo group (from 346± 60 to 345±56 mg/dL; P=NS). Baseline fibrinopeptide A levels were low in both groups, and low levels were found throughout the course of the study.
In the Parnaparin group, compared with the control, the exercise time to 1-mm ST segment depression increased from 285±126 to 345±168 seconds (P=.008; Table 3 ). The increment was also associated with an increase in the rate-pressure product at 1-mm ST segment depression from 17 310±4030 to 18 890±4740 (P=.07). In this respect, the changes observed in the placebo group were not statistically significant. The time (Fig 3) . Neither the improvement in exercise duration at 1-mm ST depression nor the change in peak ST depression at peak exercise was significantly related to the changes in fibrinogen level (r=-.117 and .105, respectively; both P=NS) (Fig 4) . 
